A 163-patient pivotal study showed use of Bio2 Medical's Angel combined IVC filter/central venous catheter in critically ill patients who had a high risk of acute pulmonary embolism and contraindications to anticoagulation significantly reduced clinically significant and fatal pulmonary embolism without device-related bloodstream infections in more than 1,170 days. The trial met its safety endpoints, and the device was placed and removed without incident in all patients.
Trial shows Bio2's catheter-filter combo effective against pulmonary embolism
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.